AlphaMol Secures Seed Funding with Investment from ApicHope Pharmaceutical to Advance AI-Driven Drug Discovery

Investment Circle (ID: pedaily2012) reported on May 7 that ApicHope’s subsidiary resolved to invest in ALPHAMOL SCIENCE LTD (hereinafter referred to as “AlphaMol”). Through in-depth technical collaboration with AlphaMol, ApicHope will position itself in the AI-driven innovative drug discovery sector, leverage AI technology to empower drug R&D, accelerate the implementation of its innovative drug development strategy, and enhance its core competitiveness.

It is understood that AlphaMol is a biopharmaceutical company incubated by the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, specializing in AI-assisted new drug development. Aiming to address the weakness of technical methods for new drug development in China, AlphaMol is committed to integrating computational biology, artificial intelligence, and original biotechnologies for new drug research and development. In terms of product development strategy, AlphaMol focuses on new drug development for major human diseases, particularly those related to GPCR signaling pathways.

Currently, AlphaMol has established a comprehensive new drug R&D pipeline that integrates theoretical computation with experimental validation. The company boasts a team of internationally renowned scientists specializing in GPCRs, along with a suite of proprietary core technologies in this field. Recently, the AlphaMol team achieved a major breakthrough in cryo-electron microscopy (cryo-EM) technology using native cell membranes, ushering in a new era of structure-based drug design targeting precise molecular structures.

In recent years, ApicHope has adhered to innovation-driven development and the integration of industrial resources, leveraging a multi-pronged strategy of “technology + brand + capital” to drive high-quality corporate growth. By expanding its business in first-in-class drugs and innovative projects targeting novel mechanisms through independent R&D, equity participation, and the establishment of industrial funds, ApicHope has further advanced its industrial layout in the innovative drug sector and strengthened its core competitiveness in its primary business areas.